18th week of 2021 patent applcation highlights part 11 |
Patent application number | Title | Published |
20210128543 | METHODS OF TREATMENT - The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days. | 2021-05-06 |
20210128544 | OPHTHALMIC COMPOSITIONS COMPRISING BILASTINE, A BETA-CYCLODEXTRIN AND AT LEAST ONE GELLING AGENT - The invention relates to an aqueous ophthalmic pharmaceutical composition comprising:
| 2021-05-06 |
20210128545 | COMBINATION THERAPY WITH 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)M- ETHYL)-2,2-DIFLUOROACETAMIDE - Provided herein are methods of treating, preventing, managing, and/or ameliorating hypotension related to administration of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a cancer patient, wherein the methods comprise administering a combination comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof and a glucocorticoid receptor agonist, an interleukin-1 receptor antagonist, or an interleukin-1β blocker. | 2021-05-06 |
20210128546 | Atropine Pharmaceutical Compositions - The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives. | 2021-05-06 |
20210128547 | AGGRESSIVE LIPID LOWERING THERAPY IN CORONARY ARTERY DISEASE - Methods of further reducing cardiovascular risk in subjects with coronary artery disease on moderate intensity statins. For example, methods may prevent an adverse cardiovascular event in a subject in need thereof, on a dosage of 1 mg/day pitavastatin or a pharmaceutically acceptable salt thereof, when the subject has an LDL-C concentration less than 120 mg/dL, by increasing the dosage to 4 mg/day for a therapeutically effective period of time. | 2021-05-06 |
20210128548 | EXTERNAL PREPARATION COMPRISING PYRIDONECARBOXYLIC ACID DERIVATIVE - The present invention is intended mainly to provide an external preparation that exerts a therapeutic and/or preventive effect against dermatological infections such as acne involving suppurative inflammation, and superficial infections of the skin upon being administered to a human patient once daily. For example, the present invention is an external preparation that comprises 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid and/or a pharmaceutically acceptable salt thereof as an active ingredient, and that exerts a therapeutic and/or preventive effect against a dermatological infection upon being administered to a human patient once daily. | 2021-05-06 |
20210128549 | OXYCODONE AND METHYLNALTREXONE MULTIPARTICULATES AND SUSPENSIONS CONTAINING THEM - The invention relates to a composition that can be administered orally, comprising (a) opioid multi-particulates comprising an opioid active agent, and an abuse resistant release controlling agent; and (b) opioid antagonist multi-particulates comprising an opioid antagonist, and a release controlling agent and/or a release delaying agent. It also relates to a liquid suspension that can be administered orally, comprising (a) opioid multi-particulates comprising an opioid active agent, and an abuse resistant release controlling agent; and/or (b) opioid antagonist multi-particulates comprising an opioid antagonist, and a release controlling agent and/or a release delaying agent; and wherein the multi-particulates are suspended in a liquid comprising a viscosity modifier and a flavoring agent. The invention also relates to kits containing these multi-particulates, and methods of making and using them. | 2021-05-06 |
20210128550 | AMELIORATIVE AGENT FOR CYTOKINE RELEASE SYNDROME AND SO ON - [Problem to be Solved] The present invention provides a medicament for cytokine release syndrome, autoimmune-related adverse events, macrophage activation syndrome, hemophagocytic lymphohistiocytosis or Langerhans cell histiocytosis. | 2021-05-06 |
20210128551 | PROCASPASE 3 ACTIVATION BY COMBINATION THERAPY - The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds. | 2021-05-06 |
20210128552 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO - Imidazo[1,2-α]pyridine derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT | 2021-05-06 |
20210128553 | COMBINATION COMPOSITIONS FOR IMMUNOTHERAPY - The present invention relates to therapeutic combinations comprising WNT inhibitors and methods for treating cancers using combination therapy. | 2021-05-06 |
20210128554 | ANTI-FLAVIVIRIDAE ACTIVITY OF ANTI-RETROVIRAL NON-NUCLEOSIDE (NNRTIS) AND NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS) - Compositions of non-nucleoside reverse transcriptase inhibitor (NNRTI) and/or a nucleoside reverse transcriptase inhibitor (NRTI) or combinations thereof, in the prevention and treatment of Flaviviridae infections, e.g. Zika virus. | 2021-05-06 |
20210128555 | CDK4/6 INHIBITORS AND USE THEREOF - The present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt, a solvate, a stereoisomer, or tautomer thereof, a pharmaceutical composition comprising a compound of formula (A) or formula (B), and any subgenera thereof, and use of said compounds and compositions thereof, wherein R | 2021-05-06 |
20210128556 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF - Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers. | 2021-05-06 |
20210128557 | METHODS AND COMPOSITIONS FOR PREDICTING AND PREVENTING RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA - Described in exemplary embodiments herein are methods, compositions, and kits for diagnosing, prognosing, monitoring, treating and/or preventing a hemopoietic malignancy and/or relapse thereof in a subject. In some embodiments, the methods can include determining an average cellular mass of cells in a sample from the subject and/or detecting one or more molecular signatures in one or more of the cells. In some embodiments, treatment includes administering one or more BCR-ABL tyrosine kinase inhibitors or a pharmaceutical formulation thereof, one or more pre-BCR signaling pathway inhibitors or a pharmaceutical formulation thereof, one or more p38 MAPK inhibitors or a pharmaceutical formulation thereof or any combination thereof. | 2021-05-06 |
20210128558 | Treatment Of Adipocytes - The present disclosure provides compositions comprising a lyn kinase activator and TRPM8 agonist, and to methods of: reducing blood glucose levels, weight gain, or fat depot levels; treating metabolic syndrome, Syndrome X, obesity, prediabetes, type II diabetes, type I diabetes; treating hypercholesterolemia, hypertension, coronary heart disease, diabetic neuropathy, lipodystrophy, diabetic retinopathy, erectile dysfunction, kidney disease, dyslipidemia, dyslipoproteinemia, a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, or pancreatitis; inducing the beiging of adipocytes; and preventing pancreatic beta cell degeneration. | 2021-05-06 |
20210128559 | Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof - The invention relates to quinazoline compounds, the preparation method, use, and the pharmaceutical composition thereof. The said quinazoline compounds, which are represented by Formula (I), are phosphatidylinositol 3-kinase (PI3K) inhibitors, and can be applied to prevent and/or treat PI3K activity-related diseases, such as cancer, immune diseases, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders or neurological diseases. | 2021-05-06 |
20210128560 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS - The present invention relates to a compound that is useful as an inhibitor of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising this compound and to methods of using this compound in the treatment of cancer and methods of treating cancer. | 2021-05-06 |
20210128561 | MRGX Receptor Antagonists - The invention relates to a method for preventing or treating a disease or disorder that is associated with the MrgX2 receptor. The invention also relates to MrgX2 antagonists and physiologically acceptable salts thereof. The invention also relates to pharmaceutical compositions and dosage forms comprising an MrgX2 antagonist. | 2021-05-06 |
20210128562 | INTRAVENOUS INFUSION DOSAGE FORM - The present invention refers to an intravenous infusion dosage form comprising a composition containing pemetrexed or its pharmaceutically acceptable salt, an osmagent and an aquous vehicle. The composition is present in a flexible infusion container containing an inert gas in the headspace. Additionally, a second container may be present surrounding the flexible infusion container. | 2021-05-06 |
20210128563 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS - The invention relates to N-(substituted-phenyl)-sulfonamide compounds, which are extremely useful as inhibitors of protein kinases (e.g. PERK kinase) and accordingly can be used for the treatment of cell proliferative disorders, such as cancer, or diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds. | 2021-05-06 |
20210128564 | COMPOSITIONS AND METHODS OF USE OF CIS-4-[2-{[(3S,4R)-3-FLUOROOXAN-4-YL]AMINO}-8-(2,4,6-TRICHLOROANILINO)-9H- -PURIN-9-YL]-1-METHYLCYCLOHEXANE-1-CARBOXAMIDE - Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide, alternatively named (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof. | 2021-05-06 |
20210128565 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH - Provided herein are Aminopurine Compounds having the following structures: | 2021-05-06 |
20210128566 | NOVEL FUNCTIONALIZED PURINE-2,6-DIONES AND THEIR USE IN MEDICINE - There is provided compounds of formula (I), or pharmaceutically-acceptable salts thereof, wherein R | 2021-05-06 |
20210128567 | Compositions and Methods for Cognitive, Immune and Digestive Support in Patients with Autism Spectrum Disorder - The present invention provides compositions and methods for improving the quality of life for a subject, particularly a child, diagnosed with autism spectrum disorder (ASD). In preferred embodiments, a supplement composition comprising natural or naturally-derived ingredients is delivered to a subject in the form of a chocolate bar or other candy alongside administration of an antiviral medication. Advantageously, the composition and methods can improve the immune health of the subject, along with other signs and symptoms associated with ASD, infections and other immunocompromising conditions. | 2021-05-06 |
20210128568 | SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME - The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof. | 2021-05-06 |
20210128569 | ORODISPERSIBLE FORMULATION OF VARDENAFIL - The present invention includes an orodispersible polyalcohol-free formulation containing vardenafil or a pharmaceutically acceptable salt thereof as active ingredient, as well as filler, a buffering agent, a lubricant, a sweetener, a flavoring agent and, optionally, further pharmaceutically acceptable excipients. | 2021-05-06 |
20210128570 | METHODS FOR TREATING PULMONARY FIBROSIS - The present invention provides a method of using arylpiperazine derivatives for treating pulmonary fibrosis. The method comprises a step of administering to a pulmonary fibrosis patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative. | 2021-05-06 |
20210128571 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES - The invention provides novel 6-aryl or 6-heteroaryl 4-morpholin-4-yl-pyhdine-2-one compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, diabetes, inflammatory diseases, neurodegenerative disorders, cardiovascular disorders and viral infections; wherein R | 2021-05-06 |
20210128572 | COMBINATION OF ATR KINASE INHIBITORS WITH PARP INHIBITORS - The present invention covers combinations of at least two components, component A and component B, comprising component A being an ATR kinase inhibitor, particularly Compound A, and component B being a PARP inhibitor, such as olaparib. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particurlarly for the treatment of a hyper-proliferative disease. | 2021-05-06 |
20210128573 | DOSING REGIMENS FOR USE IN TREATING MYELOFIBROSIS AND MPN-RELATED DISORDERS WITH NAVITOCLAX - The invention described herein relates to methods for treating a human subject with myelofibrosis or an MPN-related disorder, comprising administering navitoclax to the subject optionally in combination with ruxolitinib. | 2021-05-06 |
20210128574 | NOVEL USES - This invention relates to new use of dual NK-1/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof in the treatment of sex-hormone dependent diseases. | 2021-05-06 |
20210128575 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T | 2021-05-06 |
20210128576 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T | 2021-05-06 |
20210128577 | Selective HDAC6 Inhibitors - The present invention relates to novel benzohydroxamic compounds of formula (1) and (II) and pharmaceutically acceptable salts, isomers and prodrugs thereof, exhibiting a high selective inhibitory activity against histone deacetylase 6 (HDAC6) enzyme. | 2021-05-06 |
20210128578 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE - The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: | 2021-05-06 |
20210128579 | FORMULATIONS FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER - Provided herein are compositions for reducing symptoms of post-traumatic stress disorder. The compositions include a combination of an N-methyl-D-aspartate (NMDA) receptor antagonist and an anti-depression agent. | 2021-05-06 |
20210128580 | TREATMENT FOR WOLFRAM SYNDROME AND OTHER ENDOPLASMIC RETICULUM STRESS DISORDERS - The present invention generally relates to compositions and methods for treating or preventing an endoplasmic reticulum stress disorder in subjects, including compositions and methods for treating or preventing Wolfram syndrome. The present invention also relates to methods for treating symptoms of neurodegenerative diseases. | 2021-05-06 |
20210128581 | METHODS OF USE FOR TRP CHANNEL ANTAGONIST-BASED COMBINATION CANCER THERAPIES - The present invention relates to methods for treating cancer through combination therapy with a TRP channel antagonist and standard-of-care cancer agents. | 2021-05-06 |
20210128582 | METHODS OF TREATING OR PREVENTING NONALCOHOLIC STEATOHEPATITIS AND/OR PRIMARY BILIARY CIRRHOSIS - In various embodiments, the present invention provides methods of treating and/or preventing NASH and/or PBC comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 2021-05-06 |
20210128583 | INJECTABLE NEUROSTEROID FORMULATIONS CONTAINING NANOPARTICLES - The disclosure provides an injectable neurosteroid nanoparticle formulation comprising nanoparticles having a D50 of less than 2000 nm the nanoparticles comprising a neurosteroid of Formula I, | 2021-05-06 |
20210128584 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS - The invention generally pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptor can be used in methods for treating patients diagnosed with Amyotrophic Lateral Sclerosis (ALS). | 2021-05-06 |
20210128585 | SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME - Described herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use. | 2021-05-06 |
20210128586 | METHODS OF SIZING 6B,7B:15B,16B-DIMETHYLENE-3-OXO-17A-PREGN-4-ENE-21,17-CARBOLACTONE PARTICLES AND COMPOSITIONS COMPRISING THE SAME - Described herein are methods to size particles of 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as compositions comprising 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone particles having defined particle size distributions. Also described are methods of use of the resulting particles. | 2021-05-06 |
20210128587 | OMEGA-3 FATTY ACID AND VITAMIN D LEVELS TO IDENTIFY AND ATTENUATE COGNITIVE AGING IN INDIVIDUALS - A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin Dora metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and homocysteine, independently in one or more samples obtained from the subject. | 2021-05-06 |
20210128588 | PHARMACEUTICAL SPRAY COMPOSITION COMPRISING A VITAMIN D ANALOGUE AND CORTICOSTEROID - The present invention relates to a topical spray composition comprising a biologically active vitamin D derivative or analogue and a corticosteroid, and its use in the treatment of dermal diseases and conditions. | 2021-05-06 |
20210128589 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE - The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: | 2021-05-06 |
20210128590 | CYCLIC PLASMENYLETHANOLAMINES - Provided herein are cyclic plasmenylethanolamines and plasmalogen precursors of formula A, wherein R | 2021-05-06 |
20210128591 | IONIC POLYMERS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS - Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I): structure (I) or a stereoisomer, tautomer or salt thereof, wherein R | 2021-05-06 |
20210128592 | REVERSING THE UNDESIRABLE pH-PROFILE OF DOXORUBICIN VIA ACTIVATION OF A DISUBSTITUTED MALEAMIC ACID PRODRUG AT TUMOR ACIDITY - A pre-prodrug, comprising a drug, e.g., doxorubicin, which has off-target toxicity (e.g., cardiotoxicity) with respect to its antineoplastic activity, and an amine functionality of the drug incorporated into a disubstituted maleimide (DMI). The pre-prodrug may be linked to a targeting or de-targeting agent or a polar modulator, e.g., charged ligand, amino acid, peptide, etc., to increase therapeutic index. The pre-prodrug is hydrolyzed to the prodrug, having a disubstituted maleamic acid (DMA). A polar modulator such as glutamic acid prevents cellular uptake of the prodrug, but not the doxorubicin drug released from the prodrug after dissociation. The prodrug is pH sensitive, and below pH 7.0, tends to cleave to form free drug and cyclized maleic anhydride. Tumor environments tend to be more acidic, e.g., pH 6.8, than cardiac tissue, e.g., pH 7.4, and therefore the heart is spared while the drug is selectively released within a tumor. | 2021-05-06 |
20210128593 | SYNERGISTIC NUTRITIONAL NEUROPROTECTIVE COMPOSITIONS FOR AMELIORATING NEURAL DYSFUNCTION - The present invention disclosed herein provides synergistic nutritional neuroprotective compositions for ameliorating neural dysfunction. Particularly, the invention relates to synergistic, efficient, nutritional composition for comprising specific combination of decarboxylated L-arginine called agmatine sulphate and nicotinamide riboside chloride, wherein agmatine sulphate and nicotinamide riboside chloride are present in the weight ratio of 1:0.05 to 1:2 along with pharmaceutically acceptable excipients. More particularly, the present invention offers synergistic effect for ameliorating neural dysfunction encompasses cerebrovascular diseases, neurodevelopmental disorders, mood disorders, mental health disorders and like thereof. | 2021-05-06 |
20210128594 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS - The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. | 2021-05-06 |
20210128595 | METHODS AND COMPOSITIONS RELATING TO THE TREATMENT OF FIBROSIS - Described herein are methods of treating fibrosis and fibrotic diseases with certain aminoglycosides, e.g., kasugamycin derivatives thereof. | 2021-05-06 |
20210128596 | COMPOSITIONS AND METHODS FOR TREATING SEPTIC CARDIOMYOPATHY - Methods and compositions are provided for treating sepsis-associated cardiac dysfunction, specifically sepsis-induced cardiomyopathy, and for protecting the heart from sepsis-associated dysfunction and improving cardiac function in subjects having sepsis. These methods include administering compositions comprising secoisolariciresinol diglucoside (SDG) or related compounds, obtained from natural sources, such as flaxseed, or generated synthetically. | 2021-05-06 |
20210128597 | THE HSP90 ACTIVATOR AHA1 DRIVES PRODUCTION OF PATHOLOGICAL TAU AGGREGATES - Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308. | 2021-05-06 |
20210128598 | Radiation-Sterilized Biodegradable Drug Delivery Compositions - The present disclosure is directed to a method of making a composition by combining a vehicle, e.g., a single phase vehicle, and an insoluble component comprising a beneficial agent, and sterilizing the composition using ionizing radiation prior to use, wherein the beneficial agent is stable following exposure to a sterilizing dose of ionizing radiation. Related compositions and methods are provided. | 2021-05-06 |
20210128599 | METHODS AND AGENTS FOR MODULATING INFLAMMATION - Methods and agents for modulating intracellular coenzyme A levels are described for therapeutic purposes. Increasing intracellular coenzyme A increases alternate macrophage activation resulting in suppression or resolution of an immune response for benefit in treating inflammatory diseases. Decreasing intracellular coenzyme A levels decreases alternate macrophage activation which is beneficial in treating NASH/NAFLD and various fibrotic diseases as well as reversing immune suppressing activity of tumor-associated immune cells such as macrophages for the treatment of cancer. | 2021-05-06 |
20210128600 | Use of Methylation Inhibitors for the Treatment of Autoimmune Diseases - Described herein is a method for treating an autoimmune disease in a patient including administering to the patient in need thereof, a pharmaceutically effective amount of an epigenetic enzyme inhibitor. | 2021-05-06 |
20210128601 | THERAPEUTIC AGENT FOR DRY EYE CHARACTERIZED BY BEING APPLIED TO EYE OF DRY EYE PATIENT WEARING SOFT CONTACT LENS - An ophthalmic solution, which comprises diquafosol tetrasodium salt and is free from benzalkonium chloride, treats onset and/or exacerbation of dry eye symptom caused by wearing soft contact lenses. | 2021-05-06 |
20210128602 | METHODS FOR TREATMENT OR PREVENTION OF LEUKEMIA - The present disclosure relates generally to methods for preventing, ameliorating or treating leukemia. In particular, the present disclosure relates to administering a therapeutically effective amount of at least one agent to reduce the expression of synaptotagmin-binding, cytoplasmic RNA-interacting protein (SYNCRIP) to a subject diagnosed with, or at risk for acute myeloid leukemia (AML). | 2021-05-06 |
20210128603 | COMBINATION OF A MAPK/ERK PATHWAY INHIBITOR AND A GLYCOSAMINOGLYCAN FOR THE TREATMENT OF CANCER - A negatively charged glycosaminoglycan is provided for use as a medicament for the treatment of cancer A combined administration of a negatively charged glycosaminoglycan is provided in which the glycosaminoglycan is characterised by the absence of the terminal pentasaccharide of Heparin, and an inhibitor of the MAPK/ERK pathway. A combined administration of a glycosaminoglycan and a MAPK/ERK pathway inhibitor is provided as a medicament for the treatment of cancer types that exhibit a resistance towards a single MAPK/ERK pathway inhibitor treatment. | 2021-05-06 |
20210128604 | Stabilized Glycosaminoglycan Preparations and Related Methods - Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain Nitrogen containing polymers (e.g., Polylysine, Polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.) | 2021-05-06 |
20210128605 | COMPOSITION FOR PROMOTING SECRETORY IGA SECRETION - It is an objective of the present invention to provide a composition that is sufficiently safe to allow daily ingestion and that has an ability to promote the secretion of s-IgA into saliva in a continuous and age-independent manner. The above objective is achieved by the composition for promoting secretion of secretory IgA, comprising as an active ingredient Okinawa mozuku-derived fucoidan with a recommended daily intake of 1,000 mg or more. The composition has the mucosal immunostimulatory effect, anti-infection effect or anti-allergy effect and is expected to be used for ameliorating, mitigating, suppressing, treating or preventing diseases or symptoms on which these effects are expected to work, such as bacterial infection, viral infection, protozoan infection, food allergy, pollenosis, gastritis, enteritis, diarrhea, ulcerative colitis, rhinitis, bronchitis, bronchial asthma, Löffler's syndrome and stomatitis, as well as any symptoms resulting therefrom. The composition is also expected to be used in immunotherapies and induction of immunotolerance. | 2021-05-06 |
20210128606 | SULPHATED XYLANS FOR TREATMENT OR PROPHYLAXIS OF RESPIRATORY DISEASES - The present invention relates generally to agents and medicinal protocols useful in the prophylaxis and/or treatment of respiratory diseases or conditions such as asthma, allergic rhinitis and chronic obstructive pulmonary disease (COPD). More particularly, the present invention relates to the use of a sulfated xylan or a derivative or homolog thereof in the treatment of respiratory diseases or conditions. | 2021-05-06 |
20210128607 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF - One aspect of the invention provides polymer conjugated MetAP2 inhibitors. While not being bound by any particular theory, it is believed that coupling the MetAP2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of the invention, the polymer conjugated MetAP2 inhibitors are useful in methods of treating disease, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer conjugated MetAP2 inhibitor. | 2021-05-06 |
20210128608 | PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading. | 2021-05-06 |
20210128609 | ONCOLOGY TREATMENTS USING ZINC AGENTS - The invention relates to methods for treating a cancer patient comprising administering a Zn(II) agent or a Zn(II) agent/immune-oncology agent combination to provide a therapeutic benefit to the cancer patient. The methods are useful in treating a broad spectrum of human cancers, including solid tumors and blood-based cancerous cells. In particular embodiments, the treatment methods are directed to cancer types characterized by genetic instability mutations. | 2021-05-06 |
20210128610 | ENCAPSULATED ANTIMICROBIALS AND RELATED METHODS OF TREATMENT - he invention provides compositions and methods that comprise encapsulated silver diamine fluoride or other antimicrobial materials for use in treatment of dental caries, for example. | 2021-05-06 |
20210128611 | AUTOLOGOUS AND ALLOGENIC MACROPHAGES AND MONOCYTES FOR USE IN THERAPEUTIC METHODS - Provided herein are innate immune cells for use in therapeutic methods. Also described herein are pharmaceutical compositions comprising innate immune cells for use in the treatment of a variety of diseases including, but not limited to pathogenic infections, pulmonary diseases, inflammatory diseases, autoimmune diseases, and immunodeficiency. | 2021-05-06 |
20210128612 | Therapeutic Methods Involving Modulating Inflammasome Activation of Myeloid-Derived Suppressor Cells - In one aspect, a method of treating a subject having or at risk of having graft-versus-host disease (GvHD) generally includes administering to the subject a plurality of myeloid-derived suppressor cells (MDSCs) effective to ameliorate at least one symptom or clinical sign of graft-versus-host disease compared to a suitable control subject. In another aspect, a method of treating a tumor in a subject generally includes administering to the subject an anti-tumor therapy and co-administering to the subject an inflammasome inciting agent in an amount effective to increase inflammasome activation of MDSCs sufficiently to reduce suppressor function of the MDSCs. | 2021-05-06 |
20210128613 | ENGINEERED IMMUNE CELLS RESISTANT TO TUMOR MICROENVIRONMENT - The invention pertains to the field of adoptive cell immunotherapy. It provides with engineered immune cells comprising genetic alteration into genes which are involved into immune functions downregulation, especially in response to environment signals such as nutrients depletion. Such method allows the production of more potent immune cells in the context of tumors' microenvironment. | 2021-05-06 |
20210128614 | COMPOSITIONS AND METHODS FOR THE ISOLATION AND/OR GENERATION OF SPECIFIC CD4+ AND CD8+ T-CELL SUBSETS - The present disclosure relates to particular subsets of CD4+ and CD8+ T-cells, methods of isolating and generating these cells, compositions comprising these cells, and methods of treatment of a tumor or cancer by administering these cells alone or in combination with each other and/or additional therapies. | 2021-05-06 |
20210128615 | METHODS AND COMPOUNDS FOR IMPROVED IMMUNE CELL THERAPY - The present invention pertains to methods and compounds useful in a therapy involving the administration of immune cells to a patient. The method of the invention involves the modification of cells of the immune system with agonists or antagonists of immune regulators such as Interleukin-10 (IL-10) or IL-6, in order to enhance and improve the immunological potential of the immune cells for therapy. Cells modified according to the method of the invention can be administered to a patient to support a treatment of proliferative diseases such as cancer or autoimmune disorders. | 2021-05-06 |
20210128616 | PHENOTYPIC MARKERS FOR CELL THERAPY AND RELATED METHODS - Provided are methods, compositions and articles of manufacture for use in cell therapy involving the administration of one or more doses of a therapeutic T cell composition, and methods, compositions and articles of manufacture for use in the same. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the embodiments of the present disclosure, including the dose of cells or units of cells administered and/or the phenotype of administered cells, provide various advantages, such as consistent dosing, lower risk of toxicity and/or increased response in subjects administered the T cell compositions. | 2021-05-06 |
20210128617 | SYNTHETIC CARS TO TREAT IL13R-alpha-2 POSITIVE HUMAN AND CANINE TUMORS - The present disclosure provides modified immune cells or precursors thereof (e.g. T cells) comprising chimeric antigen receptors (CARs) capable of binding human IL13Rα2. Also provided are bispecific CARs, parallel CARs, tandem CARs, BiTEs, BiTE/CARs, and BiTE/BiTEs. Compositions and methods of treatment are also provided. | 2021-05-06 |
20210128618 | BCMA-TARGETED CAR-T CELL THERAPY OF MULTIPLE MYELOMA - Provided herein is a method of treating a subject who has a cancer. At least one dose of chimeric antigen receptor (CAR)-T cells comprising a CAR comprising a polypeptide is administered to the subject. The peptide comprises an extracellular antigen binding domain with at least two BCMA-binding moieties, a transmembrane domain, and an intracellular signaling domain. The dose of CAR-T cells administered to the subject is from 4.0×10 | 2021-05-06 |
20210128619 | USES OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS - Provided herein are uses of anti-B cell maturation antigen (BCMA) chimeric antigen receptors (CARs) for treating B-cell related conditions, such as BCMA-expressing cancers. | 2021-05-06 |
20210128620 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY - The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens. | 2021-05-06 |
20210128621 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY - The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens. | 2021-05-06 |
20210128622 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY - The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens. | 2021-05-06 |
20210128623 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY - The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens. | 2021-05-06 |
20210128624 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY - The present invention provides improved and/or shortened methods for expanding TLs and producing therapeutic populations of TTLs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TLs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TLs find use in therapeutic treatment regimens. | 2021-05-06 |
20210128625 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY - The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens. | 2021-05-06 |
20210128626 | PLATELET-RICH PLASMA LYSATE COMPOSITIONS AND RELATED METHODS - An acellular, anion-depleted platelet-derived peptide-rich composition comprising proteins, polypeptides and peptides <10 kDa in size, wherein the composition has anti-microbial and/or anti-inflammatory activity is disclosed. The composition can be substantially free of non-active and immunogenic factors. The composition can have a platelet-to-bacteria ratio ≥1000:1. The composition can comprise plasma at a range of ≥10% to ≤50% plasma, optionally about 10% plasma. Methods of using the composition are also disclosed. Also disclosed is a method for preparing an acellular platelet-derived peptide-rich composition having anti-microbial and/or anti-inflammatory activity, the method comprising: providing a starting material comprising platelet-rich plasma processed to contain ≥1,000,000 platelet/μL, ≤100 leukocytes/μL and ≤10 erythrocyte/μL in plasma; lysing and/or activating the starting material; contacting the starting material with an ion exchange matrix and/or a size exchange matrix; and isolating the acellular platelet-derived peptide-rich composition. | 2021-05-06 |
20210128627 | METHODS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) - Described herein are mesenchymal stem cells and populations thereof, which can be used for treating neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) disease. Methods for treating neurodegenerative diseases, such as ALS, by administering mesenchymal stem cells (MSC) cells that have been induced to secrete at least one neurotrophic factor (NTF), wherein said cell population comprises MSC-NTF cells are described. | 2021-05-06 |
20210128628 | METHODS FOR GENERATING MULTIPOTENT STEM CELLS FROM TONSILLAR BIOPSIES - The invention provides compositions comprising multipotent progenitor cells isolated from tonsillar tissue and differentiated cells derived therefrom and methods for using the cells for the treatment of diseases or disorders. | 2021-05-06 |
20210128629 | REPAIR AGENT FOR LIVING TISSUE DAMAGE AND METHOD FOR PRODUCING SAID REPAIR AGENT - In order to provide (i) a repair agent for damaged tissue and (ii) a method for producing the repair agent, the present invention uses mesenchymal stem cells cultured in a serum-free medium. | 2021-05-06 |
20210128630 | PURIFIED MESENCHYMAL STEM CELL EXOSOMES AND USES THEREOF - Provided herein are isolated exosomes from mesenchymal stem cells (MSC). Such isolated exosomes are substantially CT free of contaminants and are therapeutically active in treating various diseases (e.g., lung diseases such as BPD). The isolated MSC exosomes are identified by one or more protein markers described herein. Methods of purifying such MSC exosomes are also provided. | 2021-05-06 |
20210128631 | METHODS OF TREATING AUTISM SPECTRUM DISORDERS USING HUMAN UMBILICAL CORD TISSUE-DERIVED MESENCHYMAL STROMAL CELLS - The present disclosure provides methods of treating Autism Spectrum Disorder. More particularly, the present disclosure relates to methods of using cord blood tissue-derived mesenchymal stromal cells to treat Autism Spectrum Disorder. | 2021-05-06 |
20210128632 | Methods And Compositions For Purification Or Isolation Of Microvesicles And Exosomes - The invention relates to the isolation or extraction of exosomes. | 2021-05-06 |
20210128633 | METHODS OF TREATING EXERCISE-INDUCED PULMONARY HEMORRHAGE - Provided herein are methods of treating EIPH in a subject in need thereof. The methods comprise administering an effective amount of a pharmaceutical composition to the subject. In some embodiments, the pharmaceutical composition comprises a granuloma fluid, or a composition derived from a granuloma fluid. In some embodiments, the pharmaceutical composition comprises a cell. These pharmaceutical compositions may be administered by any suitable route of administration, and may be administered with one or more further therapeutic agents. Also provided are kits comprising pharmaceutical compositions for use with the methods provided herein. | 2021-05-06 |
20210128634 | EXOSOMES DERIVED FROM CORTICAL BONE STEM CELLS CAN AUGMENT HEART FUNCTION AFTER CARDIAC INJURY - The present invention provides an isolated population of cortical bone stem cell (CBSC)-derived exosomes, and compositions comprising the exosomes and/or RNA thereof, for promoting cardiac repair when delivered to a diseased heart. | 2021-05-06 |
20210128635 | Composition for Regenerating Hepatic Tissue - Provided is a composition for liver tissue regeneration, in particular, a composition for liver tissue regeneration for prevention or treatment of a liver disease. The composition for liver tissue regeneration includes a human dental pulp stem cell as an effective component. | 2021-05-06 |
20210128636 | FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS - Embodiments of the disclosure encompass methods and compositions for treatment of cancer utilizing fibroblasts that have been modified to enhance their ability to deliver one or more anti-cancer agents to an individual in need thereof. In particular embodiments, the fibroblasts have been modified to express on or more chemokine receptors and/or have been exposed to hypoxia to enhance their ability to home to cancer cells. In specific cases the modified fibroblasts are engineered to encompass an oncolytic virus as a tumor inhibitory agent. | 2021-05-06 |
20210128637 | METHODS FOR TREATING CARDIAC CONDITIONS - Described herein are compositions and methods of treating a cardiac condition using modified placental tissue or an extract of a placental tissue, capable of recruiting stem cells or promoting healing in vivo and in vitro. | 2021-05-06 |
20210128638 | CELLULAR, ORGAN, AND WHOLE-BODY REJUVENATION UTILIZING CORD BLOOD PLASMA AND PTEROSTILBENE - Disclosed are methods, means, and protocols for stimulation of rejuvenation in single cells, organs, and organisms by administration of cord blood derived plasma, cord blood plasma concentrates, and cord blood derived exosomes together with pterostilbene. The invention describes the previously unexpected finding that addition of pterostilbene to cord blood enhances the rejuvenation properties of cord blood. Said rejuvenation properties include telomere preservation, reduction in beta galactosidase, and retention of cellular activities. | 2021-05-06 |
20210128639 | CELL PREPARATION FOR TREATING BRAIN TUMOR - A cell preparation for treating brain tumors used in combination with a prodrug of a drug that kills, or inhibits proliferation of, tumor cells, wherein the cell preparation comprises neural stem cells derived from iPS cells or ES cells having a suicide gene, and the prodrug is a prodrug activated with an enzyme produced by expression of the suicide gene comprised in the neural stem cells is provided to solve the difficulty of obtaining neural stem cells, which is problematic, and to establish new means for treating brain tumors using neural stem cells. | 2021-05-06 |
20210128640 | HYALURONIC ACID PRODUCTION PROMOTING AGENT - An agent of the present invention comprising poultry feet or a processed product thereof, preferably a hydrolysate of an extract of poultry feet, promotes hyaluronic acid production, thereby exhibiting excellent effects of preventing or treating a joint disorder, improving skin dryness, wrinkles or skin tension, moisturizing the skin, etc. The agent is thus useful as a medicament, a quasi-drug, a cosmetic product, a food product or an animal feed. | 2021-05-06 |
20210128641 | COMPOSITIONS AND METHODS FOR TREATING SKIN AND MUCOUS MEMBRANE DISEASES - This invention relates to topical probiotic formulations for treating skin conditions. | 2021-05-06 |
20210128642 | CHOLESTEROL REDUCING COMPOSITIONS AND METHODS OF USE THEREOF - Microbes expressing cholesterol oxidoreductase (COR) proteins, methods of engineering the microbes expressing COR proteins, compositions and methods of using the microbes are provided. | 2021-05-06 |